# Enzastaurin to Treat Recurrent Brain Tumor

> **NCT00108056** · PHASE1 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 26 (actual)

## Conditions studied

- Glioma

## Interventions

- **DRUG:** Enzastaurin (LY317615) monohydronchloride

## Key facts

- **NCT ID:** NCT00108056
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-04-07
- **Primary completion:** 2014-04-01
- **Final completion:** 2014-04-01
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2019-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00108056

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00108056, "Enzastaurin to Treat Recurrent Brain Tumor". Retrieved via AI Analytics 2026-09-09 from https://api.ai-analytics.org/clinical/NCT00108056. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*